Scarica l'app Stockscreener
13.34
8.19%
-1.19
Dopo l'orario di chiusura:
13.77
0.43
+3.22%
Precedente Chiudi:
$14.53
Aprire:
$14.8
Volume 24 ore:
1.04M
Relative Volume:
2.16
Capitalizzazione di mercato:
$1.71B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+7.41%
1M Prestazione:
+4.22%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$13.13
$14.99
Intervallo di 1 settimana:
$12.20
$15.21
Portata 52W:
$11.00
$16.75
Generate Biomedicines Inc Stock (GENB) Company Profile
Nome
Generate Biomedicines Inc
Settore
Industria
Telefono
888-469-0055
Indirizzo
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
13.34 | 1.86B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2026-03-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-03-24 | Iniziato | Goldman | Buy |
| 2026-03-24 | Iniziato | Guggenheim | Buy |
| 2026-03-24 | Iniziato | Morgan Stanley | Overweight |
| 2026-03-24 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Generate Biomedicines Inc Borsa (GENB) Ultime notizie
This AI biotech stock landed a $10.4 million Nvidia investment - MSN
symbol__ Stock Quote Price and Forecast - CNN
Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer? - simplywall.st
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment - simplywall.st
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment - Yahoo Finance
A Deep Dive Into Nvidia’s Latest Portfolio Moves - Investing.com
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Generate Biomedicines (GENB) News Flow - Moomoo
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - The Chronicle-Journal
Trades UpdateBuying More Generate BiomedicinesDeepDive - Moomoo
AI Protein Design Market 2026-2033 | Market Growth to FY (Q2) - openPR.com
Flagship entities disclose large GENB holdings, Flagship Pioneering holds 48.9% (GENB) - Stock Titan
Generate Biomedicines (NASDAQ: GENB) exec Michael Nally holds 5.2% stake - Stock Titan
GENB : Generate Biomedicines, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
GENB: Generate Biomedicines, Inc.Brokerage Recommendations Chart - Zacks Investment Research
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Programmable Biology: Will GENB Generate Investor Interest? - RTTNews
Generate Biomedicines, Inc. Stock 12‑Month Price Target Raised to $25.4, Implies 57% Upside - TradingView
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines, Inc. (GENB) Ps Ratio (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Enterprise Value - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Free Cash Flow (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (Quarterly) - Zacks Investment Research
Dividend HistoryGenerate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Book Value - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Price To Free Cash Flow - Zacks Investment Research
All News for GENB : Generate Biomedicines, Inc. - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Price To Cash Flow - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Eps Diluted (TTM) - Zacks Investment Research
Generate Biomedicines (GENB) Earnings Date and Reports 2026 - MarketBeat
Should I buy Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Net Income (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Total Expenses (Quarterly) - Zacks Investment Research
What is the current Price Target and Forecast for Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Cash From Operations (TTM) - Zacks Investment Research
Number of shareholders of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB : Generate Biomedicines, Inc. Key Company Details - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Beta - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Dividend (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Total Long Term Debt (Quarterly) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Gross Margin (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Total Liabilities - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Cash From Financing (Quarterly) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Revenue (TTM) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) - Zacks Investment Research
Generate Biomedicines, Inc. (GENB) Price Book Value - Zacks Investment Research
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Inc Azioni (GENB) Dati Finanziari
Non sono disponibili dati finanziari per Generate Biomedicines Inc (GENB). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Generate Biomedicines Inc Azioni (GENB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grous Beth | Chief People Officer |
Mar 02 '26 |
Buy |
16.00 |
300 |
4,800 |
300 |
| Silvers Jason | President & CFO |
Mar 02 '26 |
Buy |
16.00 |
2,000 |
32,000 |
1,000 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
| Mendillo Jane L | Director |
Mar 02 '26 |
Buy |
16.00 |
1,500 |
24,000 |
1,500 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):